Within the TRAMP-C2 prostate cancer tumor model, our group was able to show that the combination treatment of Ad-LIGHT with a prostate tumor associated antigen tumor vaccine (PSCA trivax) performed much better than Ad-LIGHT treatment alone (55). This evidence concerns the gene TNFSF14 and neoplasm.